Clover Health Posts $6.4M Q3 Profit, Raises Full-Year 2026 Guidance Across All Metrics
CLOV has more than doubled off its 52-week low of $1.58.
Summary
Clover Health reported $6.4M of Q3 2026 net income versus a $24.4M loss a year ago on 53% revenue growth, and raised full-year 2026 guidance across revenue, net income, gross profit and Adjusted EBITDA. It also named Clay Thornton permanent CFO.
Key Events · Earnings and Guidance · CLOV
-
Q3 Swing to $6.4M Profit
Third quarter 2026 GAAP net income of $6.4M versus a $(24.4)M loss in Q3 2025, on total revenues of $759.3M, up 52.9% year-over-year.
-
Full-Year 2026 Guidance Raised
Revenue guidance lifted to $2.97-3.00B from $2.92-3.00B, GAAP net income to $25-35M from $20-35M, gross profit to $540-555M from $525-555M, and Adjusted EBITDA to $75-85M from $70-85M.
-
Margins Improve on Membership Growth
Insurance benefits expense ratio fell 240 bps to 91.1% while average Medicare Advantage membership rose 46.3% to 158,383; Adjusted EBITDA was $16.1M versus $2.1M a year ago.
-
CFO and CAO Made Permanent
Clay Thornton, interim CFO since March 30, 2026, was appointed CFO effective November 4, 2026 at a $450,000 salary plus a $1.5M RSU grant; Joseph Oldakowski was named Chief Accounting Officer at $410,000 plus $850,000 in RSUs.
Analysis · CLOV · Finance
Clover turned a $24.4M year-ago loss into $6.4M of Q3 net income and lifted every full-year 2026 target, including GAAP net income to $25-35M — which would be its first profitable year. Revenue grew 53% to $759M while the benefits expense ratio improved 240 bps to 91.1%, showing the growth is coming with better margins rather than bought with underpricing. The 5-Star PPO rating covering ~98% of members underpins 2027 growth expectations. The main caveat is that the quarter's profit is thin relative to $759M of revenue, so the full-year number depends on Q4 holding up.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLOV was trading at $4.67 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $1.58 to $5.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.